<DOC>
	<DOCNO>NCT00660023</DOCNO>
	<brief_summary>This single-arm study ass efficacy safety monthly administration intravenous methoxy polyethylene glycol-epoetin beta ( CERA/Mircera ) maintenance hemoglobin ( Hb ) level participant dialysis chronic renal anemia routine clinical practice Hungary . Participants currently receive maintenance treatment intravenous epoetin darbepoetin receive monthly injection Mircera , start dose derive erythropoiesis-stimulating agent ( ESA ) dose receive .</brief_summary>
	<brief_title>A Study Intravenous Mircera Participants With Chronic Renal Anemia Who Are Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adults great equal ( â‰¥ ) 18 year age Chronic renal anemia Continuous stable intravenous subcutaneous maintenance epoetin darbepoetin therapy previous month Regular longterm hemodialysis therapy mode dialysis previous 3 month Transfusion red blood cell previous 2 month Poorly control hypertension Significant acute chronic bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>